如何应用无创产前检测进行红细胞和血小板抗原分型
本文综述无创产前检测(NIPT)用于红细胞和血小板抗原分型的技术进展与临床应用,涵盖胎儿和新生儿溶血病(HDFN)及胎儿和新生儿同种免疫性血小板减少症(FNAIT)的产前管理,强调避免假阳性和假阴性结果,并为临床提供实用工具。
要点
- NIPT利用孕妇血浆中的游离胎儿DNA(cff-DNA)进行胎儿抗原分型,替代羊膜穿刺等有创方法。
- NIPT最初用于恒河猴D抗原分型,现已扩展至多种血型抗原。
- NIPT需同时防止假阳性和假阴性结果,准确的抗原分型结果对指导临床决策至关重要。
核心结论
- NIPT已成为管理同种免疫妊娠的重要手段,准确的抗原分型结果对指导临床决策至关重要。
- 未来几十年,HDFN和FNAIT病例的个性化产前治疗将出现更多可能性。
研究设计与样本
- 本文为综述,描述NIPT用于红细胞和血小板抗原分型的发展历程并提供临床实用工具。
主要发现
- 孕妇同种免疫可导致HDFN和FNAIT,HDFN可能引起严重贫血、胎儿水肿和胎儿死亡,FNAIT可能导致颅内出血和脑损伤。
- 传统有创胎儿抗原分型方法如羊膜穿刺存在流产风险。
- 孕妇血浆中游离胎儿DNA(cff-DNA)的发现使安全的NIPT成为可能。
- NIPT最初用于恒河猴D抗原血型分型,现已覆盖多种血型抗原,技术进步进一步提高了准确性。
- NIPT面临低cff-DNA比例和复杂遗传变异等挑战。
临床怎么用
- NIPT用于同种免疫妊娠管理时,需防止假阳性和假阴性结果。
- 准确的NIPT血型抗原分型结果对指导临床决策至关重要。
局限性
- NIPT面临低cff-DNA比例和复杂遗传变异等挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alloimmunization during pregnancy occurs when a mother produces antibodies against fetal antigens, leading to complications like hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT). HDFN involves destruction of fetal red blood cells, potentially causing severe anemia, hydrops fetalis, and fetal death. FNAIT affects fetal platelets and possibly endothelial cells, resulting in risk of intracranial hemorrhage and brain damage. Traditional invasive methods for fetal antigen genotyping, like amniocentesis, carried miscarriage risks. The discovery of cell-free fetal DNA (cff-DNA) in maternal plasma enabled safe, noninvasive prenatal testing (NIPT). Initially used for Rhesus antigen D blood group typing, NIPT now covers various blood group antigens. Advances in technology have further enhanced the accuracy of NIPT. Despite challenges such as low cff-DNA fractions and complex genetic variations, NIPT has become essential in managing alloimmunized pregnancies. In NIPT it is important to prevent both false-positive results and false-negative results. Particularly in the coming decades, more possibilities for personalized antenatal treatment for HDFN and FNAIT cases will become apparent and accurate NIPT blood group antigen typing results are crucial for guiding clinical decisions. In this paper we describe this journey and provide practical tools for the clinic.
引用
- van 't Oever RM, Verweij EJT, de Haas M, et al. How I use noninvasive prenatal testing for red blood cell and platelet antigens. Blood. 2025. PMID: 39786415. doi:10.1182/blood.2023022893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。